Skip to Main Content

Paper Details

Therapeutic Vulnerability to ATR Inhibition in Concurrent <i>NF1</i> and <i>ATRX</i>-Deficient/ALT-Positive High-Grade Solid Tumors.
Cancers (Basel)
9
2022
ALT, ATR, ATRX, ATRX mutations, Cancer, Cancer cells, Cell lines, High, High-Grade Solid Tumors, JHH-CRC65, JHH-NF1-GBM1 cell line, JHH-NF1-GBM1), MEK, MPNST, MPNST cell line, NF1, NF1 and ATRX deficiency, NF1)-associated, NF1-associated, NF1-associated ATRX mutant glioblastoma cell line, NF1-deficient MPNST, NF1-deficient MPNST cell lines, NF1-deficient and associated tumors, NF1-deficient sporadic glioblastomas, NF1-derived sarcoma cell line, NF90, Neurofibromatosis Type 1 (, SF188, ST88-14, TERC, U251, U251 cells, U251 glioma, U251 glioma cells, and, glioma, glioma cell line SF188, malignant, malignant solid tumors, solid tumors, telomeres, temozolomide
Author NameAffiliation
Charles G EberhartJohns Hopkins University School of Medicine
Charles G EberhartJohns Hopkins University School of Medicine
Christine A PratilasJohns Hopkins University School of Medicine
Christine A PratilasJohns Hopkins University School of Medicine
Jaishri O BlakeleyJohns Hopkins University School of Medicine
Jaishri O BlakeleyJohns Hopkins University School of Medicine
Karlyne M ReillyNational Cancer Institute
Karlyne M ReillyNational Cancer Institute
Fausto J RodriguezJohns Hopkins University School of Medicine
Fausto J RodriguezJohns Hopkins University School of Medicine
Fausto J RodriguezDavid Geffen School of Medicine, University of California Los Angeles (university of california los angeles)
Fausto J RodriguezJohns Hopkins University School of Medicine
Fausto J RodriguezJohns Hopkins University School of Medicine
Fausto J RodriguezDavid Geffen School of Medicine, University of California Los Angeles (university of california los angeles)
  • 1 - 14

Datasets